Oseltamivir Pharmacokinetics in Morbid Obesity

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01002729

Acronym

OPTIMO

Enrollment

Registered

2009-10-27

Start date

2009-11-30

Completion date

2009-12-31

Last updated

2011-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Morbid Obesity

Keywords

Oseltamivir Pharmacokinetics Obesity, Oseltamivir Pharmacokinetics in Obesity

Brief summary

This trial asks the question: do people of much greater than average body weight need more of a drug called oseltamivir than current recommendations suggest. Oseltamivir is a drug given to people who have influenza, and currently is also being used to fight the new H1N1 influenza. Some people of larger than average body weight require larger amounts of drugs to see the same effects as others of an average body weight. No studies have ever been conducted looking at the possibility of oseltamivir being one of those drugs. Our Study's hypothesis states that those of an above average body weight will have different amounts of drug in their blood than those of people of normal body weight if they are given the normal amount prescribed for influenza. Our study will give oseltamivir to twenty people for 7 days. Half of the people will be of normal body weight and the others will be of a much higher than normal body weight. Using blood samples the investigators will determine if the amounts of oseltamivir are significantly lower in the blood of patients in the above normal body weight group.

Interventions

OTHERPatients with a BMI < 30 given Oseltamivir

Patients with a BMI \< 30 given Oseltamivir

OTHERPatients with a BMI > 40 given Oseltamivir

Patients with a BMI \> 40 given Oseltamivir

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 55 Years

Healthy volunteers

Yes

Inclusion criteria

* Males and females aged 18 to 55 years * Written informed consent * Subjects without medical history, physical finding or laboratory finding, which, in the opinion of the investigator, could pose a safety concern or interfere with the protocol.

Exclusion criteria

* Allergy to oseltamivir * Blood donation within 3 months before oseltamivir administration * Medications that may interfere with the disposition of oseltamivir (e.g. probenecid) * Anemia * Estimated Creatinine clearance \< 60 ml/min (As calculated by the modified Cockcroft Gault equation below) Creatinine Clearance= (140-Age) x 1.2 x Adjusted Body weight (x 0.85 if female) Serum Creatinine (umol/L) Adjusted body weight = Ideal body weight + \[0.4 (Actual Bodyweight-Ideal Body Weight)\] * Gastrectomy * Enterectomy (or any other surgical procedure that would interfere with absorption) * Clinically significant haematological (RBC count, WBC count, WBC differential count, platelets count and haemoglobin level) or biochemical (ALT, AST, creatinine and urea) abnormalities as per the judgement of the investigator * Clinically significant cardiac conduction abnormality noted on baseline electrocardiogram. * Influenza like illness (fever and/or cough plus one of the following sore throat, fatigue, myalgia, headache) within 7 days of enrolment * Pregnancy * Inability to consume study meals provided due to special dietary requirements such as food allergies.

Design outcomes

Primary

Measure	Time frame
Serum Drug Concentration	7 Days

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026